Copyright
©The Author(s) 2022.
World J Transplant. Oct 18, 2022; 12(10): 313-324
Published online Oct 18, 2022. doi: 10.5500/wjt.v12.i10.313
Published online Oct 18, 2022. doi: 10.5500/wjt.v12.i10.313
Table 1 Clinical and demographic characteristics of kidney transplant recipients
| Characteristics | |
| Age, yr, median (range) | 46 (13-70) |
| Male/female | 49/22 |
| Living kidney donor | 22.5% |
| Deceased kidney donor | 77.5% |
| Previous kidney transplant | 7.0% |
| Preemptive transplantation | 4.2% |
| PRA(-) | 60.5% |
| Early rejection, within first 6 mo after KT | 4.2% |
| Induction therapy | |
| Basiliximab | 84.5% |
| ATG | 15.5% |
| Maintenance immune suppression | |
| Tacrolimus/mycophenolate/prednisone | 100.0% |
| Other | 0.0% |
| Distribution of underlying kidney disease | |
| Polycystic kidney disease | 22.5% |
| Primary glomerulopathies | 21.1% |
| Reflux nephropathy | 12.6% |
| Diabetes mellitus | 4.2% |
| Nephrosclerosis/hypertension | 4.2% |
| Urinary tract infections/ stones | 3.7% |
| Other | 16.2% |
| Unknown | 15.5% |
- Citation: Vagiotas L, Stangou M, Kasimatis E, Xochelli A, Myserlis G, Lioulios G, Nikolaidou V, Panteli M, Ouranos K, Antoniadis N, Maria D, Papagianni A, Tsoulfas G, Fylaktou A. Effect of panel reactive antibodies on T cell immunity reinstatement following renal transplantation. World J Transplant 2022; 12(10): 313-324
- URL: https://www.wjgnet.com/2220-3230/full/v12/i10/313.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i10.313